Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jun, Ji Eun | - |
dc.contributor.author | Jeong, In Kyung | - |
dc.contributor.author | Yu, Jae Myung | - |
dc.contributor.author | Kim, Sung Rae | - |
dc.contributor.author | Lee, In Kye | - |
dc.contributor.author | Han, Kyung-Ah | - |
dc.contributor.author | Choi, Sung Hee | - |
dc.contributor.author | Kim, Soo-Kyung | - |
dc.contributor.author | Park, Hyeong Kyu | - |
dc.contributor.author | Mok, Ji-Oh | - |
dc.contributor.author | Lee, Yong-ho | - |
dc.contributor.author | Kwon, Hyuk-Sang | - |
dc.contributor.author | Kim, So Hun | - |
dc.contributor.author | Kang, Ho Cheol | - |
dc.contributor.author | Lee, Sang Ah | - |
dc.contributor.author | Lee, Chang Beom | - |
dc.contributor.author | Choi, Kyung Mook | - |
dc.contributor.author | Her, Sung-Ho | - |
dc.contributor.author | Shin, Won Yong | - |
dc.contributor.author | Shin, Mi-Seung | - |
dc.contributor.author | Ahn, Hyo-Suk | - |
dc.contributor.author | Kang, Seung Ho | - |
dc.contributor.author | Cho, Jin-Man | - |
dc.contributor.author | Jo, Sang-Ho | - |
dc.contributor.author | Cha, Tae-Joon | - |
dc.contributor.author | Kim, Seok Yeon | - |
dc.contributor.author | Won, Kyung Heon | - |
dc.contributor.author | Kim, Dong-Bin | - |
dc.contributor.author | Lee, Jae Hyuk | - |
dc.contributor.author | Lee, Moon-Kyu | - |
dc.date.accessioned | 2021-08-31T11:34:28Z | - |
dc.date.available | 2021-08-31T11:34:28Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-02 | - |
dc.identifier.issn | 2233-6079 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/57864 | - |
dc.description.abstract | Background: Cardiovascular risk remains increased despite optimal low density lipoprotein cholesterol (LDL-C) level induced by intensive statin therapy. Therefore, recent guidelines recommend non-high density lipoprotein cholesterol (non-HDL-C) as a secondary target for preventing cardiovascular events. The aim of this study was to assess the efficacy and tolerability of omega-3 fatty acids (OM3-FAs) in combination with atorvastatin compared to atorvastatin alone in patients with mixed dyslipidemia. Methods: This randomized, double-blind, placebo-controlled, parallel-group, and phase III multicenter study included adults with fasting triglyceride (TG) levels >= 200 and <500 mg/dL and LDL-C levels <110 mg/dL. Eligible subjects were randomized to ATOMEGA (0M3-FAs 4,000 mg plus atorvastatin calcium 20 mg) or atorvastatin 20 mg plus placebo groups. The primary efficacy endpoints were the percent changes in TG and non-HDL-C levels from baseline at the end of treatment. Results: After 8 weeks of treatment, the percent changes from baseline in TG (-29.8% vs. 3.6%, P <0.001) and non-HDL-C (-10.1% vs. 4.9%, P<0.001) levels were significantly greater in the ATOMEGA group (n=97) than in the atorvastatin group (n =103). Moreover, the proportion of total subjects reaching TG target of <200 mg/dL in the ATOMEGA group was significantly higher than that in the atorvastatin group (62.9% vs. 22.3%, P< 0.001). The incidence of adverse events did not differ between the two groups. Conclusion: The addition of OM3-FAs to atorvastatin improved TG and non-I IDL-C levels to a significant extent compared to atorvastatin alone in subjects with residual hypertriglyceridemia. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN DIABETES ASSOC | - |
dc.subject | CORONARY-HEART-DISEASE | - |
dc.subject | DENSITY-LIPOPROTEIN CHOLESTEROL | - |
dc.subject | CARDIOVASCULAR-DISEASE | - |
dc.subject | EICOSAPENTAENOIC ACID | - |
dc.subject | TRIGLYCERIDE LEVELS | - |
dc.subject | FATTY-ACIDS | - |
dc.subject | RISK | - |
dc.subject | DYSLIPIDEMIA | - |
dc.subject | ATORVASTATIN | - |
dc.subject | INDIVIDUALS | - |
dc.title | Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Kyung Mook | - |
dc.identifier.doi | 10.4093/dmj.2018.0265 | - |
dc.identifier.scopusid | 2-s2.0-85080925936 | - |
dc.identifier.wosid | 000517786100007 | - |
dc.identifier.bibliographicCitation | DIABETES & METABOLISM JOURNAL, v.44, no.1, pp.78 - 90 | - |
dc.relation.isPartOf | DIABETES & METABOLISM JOURNAL | - |
dc.citation.title | DIABETES & METABOLISM JOURNAL | - |
dc.citation.volume | 44 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 78 | - |
dc.citation.endPage | 90 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002561409 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | CORONARY-HEART-DISEASE | - |
dc.subject.keywordPlus | DENSITY-LIPOPROTEIN CHOLESTEROL | - |
dc.subject.keywordPlus | CARDIOVASCULAR-DISEASE | - |
dc.subject.keywordPlus | EICOSAPENTAENOIC ACID | - |
dc.subject.keywordPlus | TRIGLYCERIDE LEVELS | - |
dc.subject.keywordPlus | FATTY-ACIDS | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | DYSLIPIDEMIA | - |
dc.subject.keywordPlus | ATORVASTATIN | - |
dc.subject.keywordPlus | INDIVIDUALS | - |
dc.subject.keywordAuthor | Atorvastatin | - |
dc.subject.keywordAuthor | Fatty acids | - |
dc.subject.keywordAuthor | omega-3 | - |
dc.subject.keywordAuthor | Hypertriglyceridemia | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.